NWBO: Once In A Decade Best Stock Investment -- Regulatory Approvals Coming! [Dec10, 2022 在第一页加了中文简述]

Laughable data release today re inflation: it's around 5.7% in Canada in March, and 8.5% in the US. In NWBO land, we continue march today, despite slower in speed. It's healthy to take a break before next major move.

1649790932624.png




1649791048343.png
 
Mark this day Ladies and Gentlemen. It may the beginning of new start for prosperousness for all parties involved. Below is a summary by an investors Chiugray:

"Thanks for the great examples of company valuations. It just makes me think about the potential, depth, and breadth of the DCVax platform:
- A first-in-class, cancer treatment technology (efficacy, basically no toxicity, quality of life, and potential for SOC and "cure")
- Broad patent protection
- Scalable manufacturing (Flaskworks, low cost)
- Validation (promising upcoming clinical trial data of actual patient's long term survival, and proving this efficacy against GBM, the emperor of all cancers)
- Personalized treatment (autologous)
- Address all solid cancers (DCVax-Direct)
- Continual optimization (modular/modulate, Linda Liau, UCLA combination treatments, e.g. DCVax + CI + CSF1R + poly ICLC)
- Systemic immune response (DCs use the entire immune system, adapts, and including immune memory to prevent cancer recurrence. Treats the entire body, addresses issue of cancer metastases. It is not a T-cell-only or a single target type, like many others are.)
- Broad potential for future applications (guessing but maybe as a prophylactic treatment for those with early stage cancers, or anything the immune system regulates)"
 
NWBO upcoming conferences and catalysts (courtesy of Nix59):

inquisitive-cress-c5d.notion.site

$NWBO upcoming dates | Notion

May 2 - Linda M. Liau, distinguished UCLA professor, neurosurgeon, and brain tumor expert, who served as the principal investigator for Northwest Biotheraputics’ DCVax-L phase III study, speaking at AANS (American Association of Neurological Surgeons) re Glioblastoma. - https://t.co/uizFandHtV
inquisitive-cress-c5d.notion.site inquisitive-cress-c5d.notion.site
 
As expected the market is heading to bear market as FED and other central banks raise rates and QT (they have been forced their hands, not willing in effect which makes thing worse).

NWBO will continually appreciate in price into May and at least early June in anticipation of major news. This is in a sense a binary event stock, more or less isolated from the general market.

Almost seven figure invested in this now (more than 90% of all my stock value) while holding a large sum of cash for a pounce when the market is well into the bear market. this time it may not come out of the bear hole too quickly because it may be a recession-sustained bear market. Could be a tough years ahead.
 
最后编辑:
Back above $1. Depending on whether the news is imminent or once again delays without clear explanation, the price may be volatile or heads north and never looks back.
 
Our Linda Liau, Principal Investigator of DCVax-L trial for GBM, the deadest form of brain cancer, and Stupp who laid the foundation for the Stupp protocol, ie., the standard of care for the treatment of glioblastoma (GBM) since its publication in 2005, today take the same stage at 2022AANS meeting at Philadelphia.

Both had criticized one another before re NWBO's DCVax-L trial and the first FDA approvel brain cancer treating device Optune which Stupp served as its Principal Investigator. Now Stupp is a consultant for NWBO. Amazing how things have developed so far.
 
NWBO 最近兩天終於有奌生命跡象
 
Now on this eventful day as FED is pause to raise interest rate by 0.5%, there is some retail excitement which cannot be ignored re NWBO:

Our fellow investor MD Dr. Gregory Zivic on twitter:

1651672191600.png


1651672231680.png


Then, this communication (courtesy of as kusterer on ihub):

"An email today to the Acadian members of the NYAS :" or Frontiers in Cancer Immunotherapy. In addition to newly added speakers Dr. Ivana Djuretic, PhD, from Asher Biotherapeutics and Dr. Linda Liau from UCLA, we posted the competitively selected short talk presentations and the panelists who will be discussing “How to turn a cold tumor into a hot tumor?”.

Don’t miss Dr. Liau’s presentation! In her lecture "Autologous Tumor Lysate-loaded Dendritic Cell Vaccination for Glioblastoma," she will be sharing exciting updates from her Phase 3 Glioblastoma Multiforme clinical trial." "

Noting: "she will be sharing exciting updates from her Phase 3 Glioblastoma Multiforme clinical trial."
 

Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma To Be Made At New York Academy Of Sciences​

Northwest Biotherapeutics Logo. (PRNewsFoto/Northwest Biotherapeutics, Inc.)
News provided by
Northwest Biotherapeutics
May 04, 2022, 11:35 ET

Share this article​

BETHESDA, Md., May 4, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported that a presentation entitled "Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination for Glioblastoma" will be made on May 10, 2022 at 11:10 a.m., by Dr. Linda Liau at the Frontiers of Cancer Immunotherapy Conference of the New York Academy of Sciences.
This presentation can be viewed virtually by registering online at the Academy's website at https://events.nyas.org/event/28ca5e39-51a7-4e73-be3d-78089c92d596/summary
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both North America and Europe. The Company has a broad platform technology for DCVax® dendritic cell-based vaccines. The Company's lead program is a 331-patient Phase III trial of DCVax®-L for newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an "orphan disease." The Company has also developed DCVax®-Direct for inoperable solid tumor cancers. It has completed a 40-patient Phase I trial and, as resources permit, plans to pursue Phase II trials. The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania.
Disclaimer
Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "design," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We cannot guarantee that we actually will achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks related to the Company's ability to achieve timely performance of third parties, risks related to whether the Company's products will demonstrate safety and efficacy, risks related to the Company's ongoing ability to raise additional capital, and other risks included in the Company's Securities and Exchange Commission ("SEC") filings. Additional information on the foregoing risk factors and other factors, including Risk Factors, which could affect the Company's results, is included in its SEC filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
CONTACTS
Dave Innes
804-513-4758
dinnes@nwbio.com
Les Goldman
240-234-0059
lgoldman@nwbio.com
SOURCE Northwest Biotherapeutics
 
Wrote a letter to conference organizers asking them to accommodate Linda's presentation to be featured and Linda as keynote speaker while expressing my gratitude for their last minute accommodation of putting Linda's presentation in agenda despite her later-than-required entry.

On a side note on FED, I think it had once again made a mistake saying not seriously consider any 75bps rate hikes in the future, and I believe if the inflation is to be brought back to 2% range, FED has to resort to some outsized rate hikes if necessary. There will be no other ways around.

As a result, Powell cheered the market temporarily but fooled retail investors. Maybe that's what FED is all about after all!
 
最后编辑:
Trading volume continually increases while price has been rising sharply high in recent days. Today's volume is about 6 times the average volume, which amounts only about 1.5% of share outstanding. If May 10 is truly the day, the volume may be skyrocket high.
 
Dr Liau is presenting her work with DC's not NWBO TLD ?
 
您必须登录或注册才可回复。
后退
顶部